Jorge Labrador
Overview
Explore the profile of Jorge Labrador including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
72
Citations
638
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Boluda B, Rodriguez-Veiga R, Sargas C, Ayala R, Larrayoz M, Chillon M, et al.
Cancers (Basel)
. 2025 Mar;
17(5).
PMID: 40075701
Background/objectives: This PETHEMA PCR-LMA study aimed to evaluate whether mutations detected by NGS (VAF cut-off of ≥5%) correlate with NPM1, FLT3-ITD, FLT3-TKD, IDH1, and IDH2 mutations detected using conventional PCR...
2.
Colmenares R, Alvarez N, Barragan E, Boluda B, Larrayoz M, Chillon M, et al.
Haematologica
. 2025 Feb;
PMID: 40013390
Not available.
3.
Serrano J, Martinez-Cuadron D, Gil C, Bernal T, Tormo M, Martinez-Sanchez P, et al.
Transplant Cell Ther
. 2025 Feb;
PMID: 39956320
It is widely accepted that allogeneic hematopoietic stem cell transplantation (allo-HSCT) is the sole potentially curative option available for secondary acute myeloid leukemia (sAML). However, clinical factors impacting outcomes after...
4.
Fernandez-Castillejo S, Badia J, de la Cruz-Merino L, Garcia-Sancho A, Carnicero-Gonzalez F, Palazon-Carrion N, et al.
Cancers (Basel)
. 2025 Feb;
17(3).
PMID: 39941898
Patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) who are ineligible for high-dose chemotherapy have limited treatment options and poor life expectancy. The purpose of this study...
5.
Navas-Acosta J, Hernandez-Sanchez A, Gonzalez T, Villaverde Ramiro A, Santos S, Miguel C, et al.
Cancers (Basel)
. 2025 Jan;
16(24.
PMID: 39766099
Adult B-cell acute lymphoblastic leukemia (B-ALL) is characterized by genetic heterogeneity and a high relapse rate, affecting over 40% of adults. However, the mechanisms leading to relapse in adults are...
6.
Lloret-Madrid P, Boluda B, Martinez-Lopez J, Bergua J, Rodriguez Arboli E, Labrador J, et al.
Cancer
. 2025 Jan;
131(1):e35696.
PMID: 39748608
Background: Patients with secondary acute myeloid leukemia who previously received hypomethylating agents for prior myeloid neoplasms (HMA-sAML) face a dismal prognosis. Methods: The authors analyze the characteristics, therapeutic approaches, and...
7.
Salmanton-Garcia J, Marchesi F, Navratil M, Piukovics K, Del Principe M, Criscuolo M, et al.
Am J Hematol
. 2024 Dec;
100(3):358-374.
PMID: 39715069
Community-acquired respiratory viral infections (CARV) significantly impact patients with hematological malignancies (HM), leading to high morbidity and mortality. However, large-scale, real-world data on CARV in these patients is limited. This...
8.
Chatzikonstantinou T, Scarfo L, Minga E, Karakatsoulis G, Chamou D, Kotaskova J, et al.
Hemasphere
. 2024 Sep;
8(9):e70004.
PMID: 39290716
No abstract available.
9.
Clark R, Davies S, Labrador J, Loubet P, Martinez S, Morinigo H, et al.
Clin Infect Dis
. 2024 Aug;
79(4):1088-1098.
PMID: 39099085
Background: We evaluated co-administration of adjuvanted seasonal quadrivalent influenza vaccine (FLU-aQIV) and respiratory syncytial virus (RSV) prefusion F protein-based vaccine (RSVPreF3 OA) in ≥65-year-olds. Methods: This phase 3, open-label trial...
10.
Pinana J, Vazquez L, Heras I, Aiello T, Lopez-Corral L, Arroyo I, et al.
Front Oncol
. 2024 Jul;
14:1389345.
PMID: 39015498
Introduction: Scarce real-life data exists for COVID-19 management in hematologic disease (HD) patients in the Omicron era. Purpose: To assess the current clinical management and outcome of SARS-CoV-2 infection diagnosed,...